RET and plasma cell myeloma: Previous studies showed that other RTK mutants, such as FGFR3K650E in multiple myeloma, RET multiple endocrine neoplasia type 2B (RETMEN2B), and PDGFRAY289C, are also tyrosine-phosphorylated via a secretory pathway39,43–49.